Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rufinamide SCHEMBL2594153 | 0.93 | CA5A (0.87) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL460913 | 0.87 | CA5A (0.76) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL6738882 | 0.85 | CA5A (0.74) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| Rufinamide SCHEMBL230448 | 0.85 | CA5A (1.00) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| Rufinamide SCHEMBL20769779 | 0.85 | CA5A (1.00) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL10667399 | 0.84 | CA5A (0.53) | CA5ACYP2C19ALDH1A1LMNAKDM1A | |
| Rufinamide SCHEMBL17372728 | 0.84 | CA5A (0.97) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL8157820 | 0.83 | CA5A (0.71) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL15838652 | 0.83 | CA5A (0.75) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL15838648 | 0.82 | CA5A (0.69) | CA5ACYP2C19ALDH1A1LMNAKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563766-B1 | IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | LESVI LABORATORIOS SL (ES) | 2014-06-25 | — | — | EP | claimed |
| EP-2727914-A1 | Polymorph of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-carboxamide | Laboratorios Lesvi, S.L. (ES) | 2014-05-07 | — | — | EP | claimed |
| EP-2563766-A1 | IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | Laboratorios Lesvi, S.L. (ES) | 2013-03-06 | — | — | EP | claimed |
| US-20130045998-A1 | PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | LABORATORIOS LESVI, S.L. (ES) | 2013-02-21 | — | — | US | claimed |
| EP-2465853-A1 | Polymorph of rufinamide and process for obtaining it | Laboratorios Lesvi, S.L. (ES) | 2012-06-20 | — | — | EP | claimed |
| WO-2011135105-A1 | IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | LABORATORIOS LESVI, S.L. (ES) | 2011-11-03 | — | — | WO | claimed |
| EP-3250563-B1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11021449-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200399229-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10738017-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190169137-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10138214-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170349558-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20130045998-A1 | PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | LABORATORIOS LESVI, S.L. (ES) | 2013-02-21 | — | — | US | disclosed |
| EP-2465853-A1 | Polymorph of rufinamide and process for obtaining it | Laboratorios Lesvi, S.L. (ES) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465853-A1 | Polymorph of rufinamide and process for obtaining it | Laboratorios Lesvi, S.L. (ES) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012032540-A1 | PROCESS FOR PREPARATION OF FLUORINATED TRIAZOLE COMPOUND | INDOCO REMEDIES LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012025936-A2 | IMPROVED PROCESS FOR THE PREPARATION OF RUFINAMIDE | DAVULURI RAMAMOHAN RAO (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011135105-A1 | IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | LABORATORIOS LESVI, S.L. (ES) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011135105-A1 | IMPROVED PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | LABORATORIOS LESVI, S.L. (ES) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045998-A1 | PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | CYP3A5, CYP3A4, CYP4B1 | CA5A 69/4885CYP2C19 20/4885ALDH1A1 392/4885 |
| US-11021449-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | CA5A 575/4885CYP2C19 91/4885ALDH1A1 259/4885 |
| US-20170349558-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | CA5A 575/4885CYP2C19 91/4885ALDH1A1 259/4885 |
| US-20200399229-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | CA5A 575/4885CYP2C19 91/4885ALDH1A1 259/4885 |
| US-10138214-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | CA5A 575/4885CYP2C19 91/4885ALDH1A1 259/4885 |
| US-10738017-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | CA5A 575/4885CYP2C19 91/4885ALDH1A1 259/4885 |
| US-20190169137-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | CA5A 575/4885CYP2C19 91/4885ALDH1A1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.